This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignees: Sandoz Gmbh, Novartis Ag. Active years: 1982-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1982-2010
Title: Dieter Scholz: A Pioneer in Pharmaceutical Innovations
Introduction
Dieter Scholz is a notable inventor based in Vienna, Austria, recognized for his contributions to the pharmaceutical field. With a total of four patents to his name, his work primarily focuses on the development of innovative compounds that have potential therapeutic applications in treating proliferative diseases and retroviral infections.
Latest Patents
Dieter’s latest patents showcase his commitment to advancing medical science. One of his notable inventions, related to phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives, involves processes for preparing these compounds, which can be utilized for pharmaceutical compositions aimed at treating diseases such as tumors. Another significant patent pertains to 2,4-diamino-3-hydroxycarboxylic acid derivatives, where he highlights compounds that possess interesting pharmacological properties, especially as HIV proteinase inhibitors.
Career Highlights
Throughout his career, Dieter Scholz has made substantial impacts while working with esteemed companies such as Sandoz GmbH and Novartis AG. His innovative spirit and dedication to research have significantly influenced the development of new therapeutic agents that enhance patient care and treatment efficacy.
Collaborations
Dieter has collaborated with several talented individuals, including Andreas Billich and Brigitte Charpiot. These partnerships have propelled his research forward and fostered an environment of innovation that benefits the pharmaceutical industry.
Conclusion
As an inventor, Dieter Scholz exemplifies the spirit of innovation in pharmaceuticals. His dedication to developing new compounds and his ability to collaborate with top professionals in the field continue to drive advancements that may improve treatment options for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

